| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.056 | 0.06 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.06 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.06 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.055 | 0.07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.06 | 0.07 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.07 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.07 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.07 |